Clinical efficacy and safety evaluation of anlotinib in the third-line treatment of advanced lung cancer

doi:10.3969/j.issn.1672-3384.2020.04.012

SUN Xin-yuan, HE Chao-ran, LOU An-qi, YU Jing, YU Jun-xian

Clinical Medication Journal ›› 2020, Vol. 18 ›› Issue (4) : 54-57.

PDF(415 KB)

Clinical Medication Journal ›› 2020, Vol. 18 ›› Issue (4) : 54-57. DOI: 10.3969/j.issn.1672-3384.2020.04.012

Original Articles

Clinical efficacy and safety evaluation of anlotinib in the third-line treatment of advanced lung cancer

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2020, 18(4): 54-57 https://doi.org/10.3969/j.issn.1672-3384.2020.04.012

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(415 KB)

Accesses

Citation

Detail

Sections

Recommended

Please choose a citation manager

Content to export